Effect of isoflurane preconditioning on myocardial gene expression and proteomics in patients undergoing cardial valve replacement

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNRC-09000479

Enrollment

Unknown

Registered

2009-06-13

Start date

2008-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardial valve disease

Interventions

B:Isoflurane preconditioning

A:Blank controling

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. 18-60 years old, male or female; 2. Scheduled to undergoing cardial valve replacement.

Exclusion criteria

Exclusion criteria: 1. The patients who once have been underwent mitral valve dilatation or cardial valve replacement or other cardial surgery; 2. Left ventricular ejection fraction <40%; 3. Need vasoactive drugs to maintain hemodynamic stabilization; 4. With dysfunction of liver, kidney or coagulation; 5. With diabetes, primary hypertension or coronary cardial disease.

Design outcomes

Primary

Measure	Time frame
Genomics and protemics;	—

Countries

China

Contacts

Public ContactWenyan Ruan

ruanwy33@yahoo.cn+86 13739089536

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026